Indivior (INDV) Stock Overview
Develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
INDV Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Indivior PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.17 |
| 52 Week High | US$25.10 |
| 52 Week Low | US$7.33 |
| Beta | 1.02 |
| 1 Month Change | -6.08% |
| 3 Month Change | 50.36% |
| 1 Year Change | 122.36% |
| 3 Year Change | 48.05% |
| 5 Year Change | 219.59% |
| Change since IPO | 117.56% |
Recent News & Updates
Recent updates
Indivior's Strategic Turnaround Gains Traction Post-Q2 2025
Aug 05Indivior: Trying To Break Addiction
Apr 28Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025
Oct 13Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback
Jul 26Shareholder Returns
| INDV | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.1% | 10.3% | 1.2% |
| 1Y | 122.4% | -2.2% | 17.9% |
Return vs Industry: INDV exceeded the US Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: INDV exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| INDV volatility | |
|---|---|
| INDV Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INDV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INDV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1,000 | Joe Ciaffoni | www.indivior.com |
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
Indivior PLC Fundamentals Summary
| INDV fundamental statistics | |
|---|---|
| Market cap | US$2.90b |
| Earnings (TTM) | US$53.00m |
| Revenue (TTM) | US$1.17b |
Is INDV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDV income statement (TTM) | |
|---|---|
| Revenue | US$1.17b |
| Cost of Revenue | US$188.00m |
| Gross Profit | US$985.00m |
| Other Expenses | US$932.00m |
| Earnings | US$53.00m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.42 |
| Gross Margin | 83.97% |
| Net Profit Margin | 4.52% |
| Debt/Equity Ratio | -126.8% |
How did INDV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 19:47 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indivior PLC is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graham Glyn Parry | BofA Global Research |
| Brian White | Cantor Fitzgerald Europe |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |